Carlos Paya, M.D., Ph.D. is currently the Senior Advisor at Abingworth Ventures, Chair, Board of Directors at Fluidigm and Highlight Therapeutics since 2020 and Board member at BIO, Fluidigm and Mallinckrodt. Dr. Paya received his M.D. and Ph.D. from the University Complutense, Madrid, Spain. Followed by his post-doctoral training in viral immunology from Institute Pasteur, Paris, France. U.S. Board certified in Internal Medicine & Infectious Diseases from the Mayo Graduate School, Rochester, MN. During his time at Mayo Medical School, Dr. Paya was the Professor of Medicine, Immunology, and Pathology. He made numerous scientific contributions to the fields of cell biology and viral immunology and to the clinical field of immune-comprised patients; supported by multiple NIH and industry grants. Elected to the American Society of Clinical Investigation and Editorial Boards of prestigious scientific journals, NIH study sections and Collaborative Groups. Author of over 200 peer-reviewed articles. Dr. Paya’s track record as senior executive in large-cap pharma, mid-cap and start-up biotech companies. During his 8 years at Immune Design, he was CEO and President, and member of the Board. Immune Design was acquired by Merck (May 2019).